US 12,227,587 B2
Humanized complement 5A receptor 1 antibodies and methods of use thereof
Karthik Viswanathan, Waltham, MA (US); Brian Booth, Waltham, MA (US); Boopathy Ramakrishnan, Waltham, MA (US); Andrew Wollacott, Waltham, MA (US); Gregory Babcock, Waltham, MA (US); Zachary Shriver, Waltham, MA (US); and Lauren Olinski, Waltham, MA (US)
Assigned to Visterra, Inc., Waltham, MA (US)
Filed by VISTERRA, INC., Waltham, MA (US)
Filed on Jan. 17, 2024, as Appl. No. 18/415,419.
Application 18/415,419 is a division of application No. 17/575,420, filed on Jan. 13, 2022, granted, now 11,912,781.
Claims priority of provisional application 63/274,748, filed on Nov. 2, 2021.
Claims priority of provisional application 63/137,089, filed on Jan. 13, 2021.
Prior Publication US 2025/0002603 A1, Jan. 2, 2025
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 37/02 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 37/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method of making an antibody or antigen binding fragment thereof that binds complement component 5a receptor 1 (C5aR1),
wherein the method comprises culturing a host cell comprising a nucleic acid encoding the C5aR1 antibody or antigen binding fragment thereof, and culturing the cell under conditions that allow production of the antibody or antigen binding fragment thereof,
wherein the C5aR1 antibody or antigen binding fragment thereof comprises a VH region, wherein the VH comprises three heavy chain complementarity determining regions (HCDRs), wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, respectively, and
a VL region, wherein the VL comprises three light chain complementarity determining regions (LCDRs), wherein the LCDR1, LCDR2, and LCDR3 sequences comprise the amino acid sequences of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, respectively.